Regression of serous macular detachment due to peripheral exudative hemorrhagic chorioretinopathy following intravitreal bevacizumab

Andrew J. Barkmeier; Huseyin Kadikoy; Eric Holz; Petros E. Carvounis

doi:10.5301/EJO.2011.6246

Regression of serous macular detachment due to peripheral exudative hemorrhagic chorioretinopathy following intravitreal bevacizumab

Andrew J. Barkmeier, Huseyin Kadikoy, Eric Holz, Petros E. Carvounis

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

Purpose. To describe a case of exudative macular detachment secondary to peripheral exudative chorioretinopathy with a favorable anatomic and visual outcome following treatment with intravitreal bevacizumab. Methods. The medical records of a patient with peripheral exudative chorioretinopathy were reviewed. Results. Macular reattachment was achieved with a corresponding visual acuity improvement that was maintained over an uncomplicated 17-month clinical course. Conclusions. Bevacizumab may be an effective treatment option for exudative macular detachment secondary to peripheral exudative hemorrhagic chorioretinopathy.

Original language	English (US)
Pages (from-to)	506-508
Number of pages	3
Journal	European Journal of Ophthalmology
Volume	21
Issue number	4
DOIs	https://doi.org/10.5301/EJO.2011.6246
State	Published - Jul 1 2011

Keywords

Bevacizumab
Eccentric disciform degeneration
Eccentric retinal degeneration
Extramacular degeneration
Peripheral exudative hemorrhagic chorioretinopathy

ASJC Scopus subject areas

Ophthalmology

Access to Document

10.5301/EJO.2011.6246

Cite this

@article{d6f9846c153d4c76ad5d216157d2805d,

title = "Regression of serous macular detachment due to peripheral exudative hemorrhagic chorioretinopathy following intravitreal bevacizumab",

abstract = "Purpose. To describe a case of exudative macular detachment secondary to peripheral exudative chorioretinopathy with a favorable anatomic and visual outcome following treatment with intravitreal bevacizumab. Methods. The medical records of a patient with peripheral exudative chorioretinopathy were reviewed. Results. Macular reattachment was achieved with a corresponding visual acuity improvement that was maintained over an uncomplicated 17-month clinical course. Conclusions. Bevacizumab may be an effective treatment option for exudative macular detachment secondary to peripheral exudative hemorrhagic chorioretinopathy.",

keywords = "Bevacizumab, Eccentric disciform degeneration, Eccentric retinal degeneration, Extramacular degeneration, Peripheral exudative hemorrhagic chorioretinopathy",

author = "Barkmeier, {Andrew J.} and Huseyin Kadikoy and Eric Holz and Carvounis, {Petros E.}",

year = "2011",

month = jul,

day = "1",

doi = "10.5301/EJO.2011.6246",

language = "English (US)",

volume = "21",

pages = "506--508",

journal = "European Journal of Ophthalmology",

issn = "1120-6721",

publisher = "Wichtig Publishing",

number = "4",

}

TY - JOUR

T1 - Regression of serous macular detachment due to peripheral exudative hemorrhagic chorioretinopathy following intravitreal bevacizumab

AU - Barkmeier, Andrew J.

AU - Kadikoy, Huseyin

AU - Holz, Eric

AU - Carvounis, Petros E.

PY - 2011/7/1

Y1 - 2011/7/1

N2 - Purpose. To describe a case of exudative macular detachment secondary to peripheral exudative chorioretinopathy with a favorable anatomic and visual outcome following treatment with intravitreal bevacizumab. Methods. The medical records of a patient with peripheral exudative chorioretinopathy were reviewed. Results. Macular reattachment was achieved with a corresponding visual acuity improvement that was maintained over an uncomplicated 17-month clinical course. Conclusions. Bevacizumab may be an effective treatment option for exudative macular detachment secondary to peripheral exudative hemorrhagic chorioretinopathy.

AB - Purpose. To describe a case of exudative macular detachment secondary to peripheral exudative chorioretinopathy with a favorable anatomic and visual outcome following treatment with intravitreal bevacizumab. Methods. The medical records of a patient with peripheral exudative chorioretinopathy were reviewed. Results. Macular reattachment was achieved with a corresponding visual acuity improvement that was maintained over an uncomplicated 17-month clinical course. Conclusions. Bevacizumab may be an effective treatment option for exudative macular detachment secondary to peripheral exudative hemorrhagic chorioretinopathy.

KW - Bevacizumab

KW - Eccentric disciform degeneration

KW - Eccentric retinal degeneration

KW - Extramacular degeneration

KW - Peripheral exudative hemorrhagic chorioretinopathy

UR - http://www.scopus.com/inward/record.url?scp=79957858149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957858149&partnerID=8YFLogxK

U2 - 10.5301/EJO.2011.6246

DO - 10.5301/EJO.2011.6246

M3 - Article

C2 - 21240857

AN - SCOPUS:79957858149

SN - 1120-6721

VL - 21

SP - 506

EP - 508

JO - European Journal of Ophthalmology

JF - European Journal of Ophthalmology

IS - 4

ER -

Regression of serous macular detachment due to peripheral exudative hemorrhagic chorioretinopathy following intravitreal bevacizumab

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this